Information Provided By:
Fly News Breaks for July 6, 2015
VRTX
Jul 6, 2015 | 08:03 EDT
Leerink raised its price target for Vertex to $158 after the FDA approved Orkambi to treat cystic fibrosis patients 12 years and older who are homozygous for the F508del CFTR mutation. The firm views the $259,000 annual pricing as in line with consensus expectations after assuming a larger gross to net discount as compared to Kalydeco. Leerink keeps an Outperform rating on the stock.
News For VRTX From the Last 2 Days
There are no results for your query VRTX